Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%.

Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%. Ahmedabad, 11 February, 2020 Zydus Cadila has received the final approval from the USFDA to market Fluocinonide Cream USP, (US RLD - Vanos Cream) 0.1%. The drug is used to treat a variety of skin conditions (e.g., psoriasis, eczema, dermatitis, allergies, rash) and will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. The group now has 279 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗